Bedaquiline: what might the future hold?
Emily S Shaw, Neil G. Stoker, Jessica Potter, Helgard Claassen, Alasdair Leslie, Conor Tweed, Chen‐Yuan Chiang, Francesca Conradie, Hanif Esmail, Christoph Lange, Lancelot Pinto, Oxana Rucsineanu, Derek J. Sloan, Grant Theron, Phumeza Tisile, Teck Chuan Voo, Robin M. Warren, Limakatso Lebina, Marc Lipman
Abstract
Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have transformed the treatment of drug-resistant tuberculosis, offering safer and more effective oral treatment options. However, key obstacles need to be overcome to ensure global access and prevent the rapid development of resistance against this promising class of drugs. In this Personal View, building on an international workshop held in 2023, we evaluate the current evidence and suggest possible ways forward, recognising the tension between increasing use and slowing the rise of resistance. We also discuss problems in accessing bedaquiline-containing regimens, the potential widening of their use beyond drug-resistant tuberculosis, and lessons for utilising new drugs as they are developed.